Literature DB >> 25786782

Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo.

Kallanthottathil G Rajeev1, Jayaprakash K Nair, Muthusamy Jayaraman, Klaus Charisse, Nate Taneja, Jonathan O'Shea, Jennifer L S Willoughby, Kristina Yucius, Tuyen Nguyen, Svetlana Shulga-Morskaya, Stuart Milstein, Abigail Liebow, William Querbes, Anna Borodovsky, Kevin Fitzgerald, Martin A Maier, Muthiah Manoharan.   

Abstract

We recently demonstrated that siRNAs conjugated to triantennary N-acetylgalactosamine (GalNAc) induce robust RNAi-mediated gene silencing in the liver, owing to uptake mediated by the asialoglycoprotein receptor (ASGPR). Novel monovalent GalNAc units, based on a non-nucleosidic linker, were developed to yield simplified trivalent GalNAc-conjugated oligonucleotides under solid-phase synthesis conditions. Synthesis of oligonucleotide conjugates using monovalent GalNAc building blocks required fewer synthetic steps compared to the previously optimized triantennary GalNAc construct. The redesigned trivalent GalNAc ligand maintained optimal valency, spatial orientation, and distance between the sugar moieties for proper recognition by ASGPR. siRNA conjugates were synthesized by sequential covalent attachment of the trivalent GalNAc to the 3'-end of the sense strand and resulted in a conjugate with in vitro and in vivo potency similar to that of the parent trivalent GalNAc conjugate design.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  N-acetylgalactosamine (GalNAc); RNAi; asialoglycoprotein receptor (ASGPR); oligonucleotide conjugates; siRNA

Mesh:

Substances:

Year:  2015        PMID: 25786782     DOI: 10.1002/cbic.201500023

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  58 in total

Review 1.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

Review 2.  GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Authors:  Aaron D Springer; Steven F Dowdy
Journal:  Nucleic Acid Ther       Date:  2018-05-24       Impact factor: 5.486

3.  Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing.

Authors:  Samantha M Sarett; Thomas A Werfel; Linus Lee; Meredith A Jackson; Kameron V Kilchrist; Dana Brantley-Sieders; Craig L Duvall
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

Review 4.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

5.  Reversal of siRNA-mediated gene silencing in vivo.

Authors:  Ivan Zlatev; Adam Castoreno; Christopher R Brown; June Qin; Scott Waldron; Mark K Schlegel; Rohan Degaonkar; Svetlana Shulga-Morskaya; Huilei Xu; Swati Gupta; Shigeo Matsuda; Akin Akinc; Kallanthottathil G Rajeev; Muthiah Manoharan; Martin A Maier; Vasant Jadhav
Journal:  Nat Biotechnol       Date:  2018-05-14       Impact factor: 54.908

Review 6.  Selective tissue targeting of synthetic nucleic acid drugs.

Authors:  Punit P Seth; Michael Tanowitz; C Frank Bennett
Journal:  J Clin Invest       Date:  2019-01-28       Impact factor: 14.808

7.  The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo.

Authors:  Annabelle Biscans; Andrew Coles; Dimas Echeverria; Anastasia Khvorova
Journal:  J Control Release       Date:  2019-03-30       Impact factor: 9.776

Review 8.  Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver.

Authors:  Colton M Miller; Michael Tanowitz; Aaron J Donner; Thazha P Prakash; Eric E Swayze; Edward N Harris; Punit P Seth
Journal:  Nucleic Acid Ther       Date:  2018-02-09       Impact factor: 5.486

9.  Hydrophobic interactions between polymeric carrier and palmitic acid-conjugated siRNA improve PEGylated polyplex stability and enhance in vivo pharmacokinetics and tumor gene silencing.

Authors:  Samantha M Sarett; Thomas A Werfel; Irene Chandra; Meredith A Jackson; Taylor E Kavanaugh; Madison E Hattaway; Todd D Giorgio; Craig L Duvall
Journal:  Biomaterials       Date:  2016-04-21       Impact factor: 12.479

Review 10.  Knocking down disease: a progress report on siRNA therapeutics.

Authors:  Anders Wittrup; Judy Lieberman
Journal:  Nat Rev Genet       Date:  2015-09       Impact factor: 53.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.